ACTRN12621001333808招募中未知
Efficacy of mepolizumab in management of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome relapses: a pilot study
St Vincent's Hospital, Sydney0 个研究点目标入组 8 人开始时间: 2021年10月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Adult patients (18 years old and above) who are diagnosed with DRESS syndrome (based on the RegiSCAR criteria) and with eosinophil count >0.8 x 10^9/L.
排除标准
- •those with other eosinophilic disorders or concurrent parasitic infection, pregnant or breastfeeding patients, children and those who are unable to give informed consent.
研究者
相似试验
进行中（未招募）
3 期
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)Eosinophilic Granulomatosis With PolyangiitisNCT05030155Assistance Publique - Hôpitaux de Paris100
进行中（未招募）
1 期
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.EUCTR2013-004297-98-GBGlaxoSmithKline Research & Development Ltd660
进行中（未招募）
1 期
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.EUCTR2013-004297-98-ROGlaxoSmithKline Research & Development Ltd675
进行中（未招募）
1 期
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbationsMedDRA version: 16.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-004297-98-SKGlaxoSmithKline Research & Development Ltd660
进行中（未招募）
1 期
English Study evaluating safety and efficacy of mepolizumab in the treatment of COPD patients with frequent exacerbations.EUCTR2013-004297-98-DKGlaxoSmithKline Research & Development Ltd660